Acadia Pharmaceuticals (ACAD) Gross Margin (2016 - 2026)

Acadia Pharmaceuticals' Gross Margin history runs 11 years deep, the most recent figure standing at 90.75% for Q1 2026.

• In Q1 2026, Gross Margin fell 90.0% year-over-year to 90.75%; the TTM figure through Mar 2026 stood at 91.47% (down 57.0% YoY), while the FY2025 annual figure was 91.69%, up 24.0% from the prior year.
• Gross Margin was 90.75% for Q1 2026 at Acadia Pharmaceuticals, roughly flat from 90.77% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 98.59% in Q1 2023 to a low of 88.85% in Q1 2024.
• Historically, Gross Margin has averaged 93.79% across 5 years, with a median of 92.47% in 2024.
• The sharpest annual moves came in 2022 and 2024: Gross Margin soared 645 bps in 2022, then plunged 974 bps in 2024.
• A 5-year view of Gross Margin shows it stood at 98.23% in 2022, then retreated by 6 bps to 92.26% in 2023, then decreased by 1 bps to 91.6% in 2024, then fell by 1 bps to 90.77% in 2025, then declined by 0 bps to 90.75% in 2026.
• The last three Gross Margin figures came in at 90.75% (Q1 2026), 90.77% (Q4 2025), and 92.23% (Q3 2025), per Business Quant data.